NCT04079712 2026-03-18
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT07174583 2026-01-23
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
IDEAYA Biosciences
Phase 1/2 Recruiting
NCT07278479 2026-01-09
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Molecular Partners AG
Phase 1/2 Recruiting
NCT05978284 2026-01-05
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT07038096 2026-01-05
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting